Literature DB >> 21737995

Down-regulation of ATP-binding cassette transporter G1 expression by unmethylated CpG oligodeoxynucleotides in RAW 264.7 macrophages.

Jeong Min Seo1, Ji-Young Lee, Geun Eog Ji, Ji Chang You.   

Abstract

We have investigated the effect of various forms of phosphodiester cytidine-phosphate-guanosine oligodeoxynucleotides (CpG ODNs) on the production of pro-inflammatory cytokines and related genes in RAW 264.7 macrophages. Treatment with the CpG ODNs increased the expression of tumor necrosis factor α (TNF-α), IL-6, and inducible nitric oxide synthase but not interleukin-1β (IL-1β). We also investigated the effect of CpG ODNs on the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) genes which are known to facilitate cholesterol efflux from macrophages for anti-atherosclerosis. CpG 2006 significantly reduced the levels of ABCG1 mRNA as determined by real-time polymerase chain reaction, whereas ABCA1 mRNA level was not changed. Western blot analysis further confirmed the reduction of ABCG1 protein expression by CpG 2006. In addition, we also determined the protein level of peroxisome proliferator activated receptor γ (PPARγ), which is recognized as a transcriptional activator of ABC transporters, was also reduced by CpG 2006. Thus, these results suggest that ABCG1 is specifically down-regulated by CpG 2006 in a PPARγ-dependent manner in macrophages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737995      PMCID: PMC3203241          DOI: 10.3858/emm.2011.43.9.058

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  34 in total

1.  Bacterial DNA activates endothelial cells and promotes neutrophil adherence through TLR9 signaling.

Authors:  Driss El Kebir; Levente József; Wanling Pan; Lili Wang; János G Filep
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

2.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

Review 3.  The macrophage in atherosclerosis: modulation of cell function by sterols.

Authors:  D M van Reyk; W Jessup
Journal:  J Leukoc Biol       Date:  1999-10       Impact factor: 4.962

Review 4.  Genomic views of STAT function in CD4+ T helper cell differentiation.

Authors:  John J O'Shea; Riitta Lahesmaa; Golnaz Vahedi; Arian Laurence; Yuka Kanno
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

Review 5.  Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

Authors:  Jörg Vollmer; Arthur M Krieg
Journal:  Adv Drug Deliv Rev       Date:  2009-01-13       Impact factor: 15.470

Review 6.  Toll-like receptor signaling pathways--therapeutic opportunities.

Authors:  Jiankun Zhu; Chandra Mohan
Journal:  Mediators Inflamm       Date:  2010-10-17       Impact factor: 4.711

Review 7.  Obesity, inflammation, and insulin resistance.

Authors:  Steven E Shoelson; Laura Herrero; Afia Naaz
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

8.  ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins.

Authors:  Nan Wang; Debin Lan; Wengen Chen; Fumihiko Matsuura; Alan R Tall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

Review 9.  Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men.

Authors:  Elena Rigamonti; Giulia Chinetti-Gbaguidi; Bart Staels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-06       Impact factor: 8.311

10.  Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses.

Authors:  Kunihiko Kitagaki; Vipul V Jain; Thomas R Businga; Iftikhar Hussain; Joel N Kline
Journal:  Clin Diagn Lab Immunol       Date:  2002-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.